HCPCS Level II drug code
J0742 — Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
In short
J0742 is the HCPCS Level II code for injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg. CMS assigns NDCs for Recarbrio to it. The Medicare Part B payment limit is $2.696 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
- Short descriptor
- Inj imip 4 cilas 4 releb 2mg
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jul 1, 2020
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the units to build the claim line.
NDCs billed under J0742
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 1 NDC to J0742 for Recarbrio. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Recarbrio | 00006-3856-02 | Merck Sharp & Dohme LLC | 25 × 1 | 3,125 |
J0742: common questions
- Is J0742 a CPT code?
- No. J0742 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J0742?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 1 NDC under J0742, for Recarbrio. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J0742?
- $2.696 per 4 mg-4 mg-2 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.